552 related articles for article (PubMed ID: 38570490)
1. Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.
Wang J; Li B; Luo M; Huang J; Zhang K; Zheng S; Zhang S; Zhou J
Signal Transduct Target Ther; 2024 Apr; 9(1):83. PubMed ID: 38570490
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
[TBL] [Abstract][Full Text] [Related]
3. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
4. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
Mardekian SK; Bombonati A; Palazzo JP
Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
[TBL] [Abstract][Full Text] [Related]
5. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
6. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
7. Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ.
Tokura M; Nakayama J; Prieto-Vila M; Shiino S; Yoshida M; Yamamoto T; Watanabe N; Takayama S; Suzuki Y; Okamoto K; Ochiya T; Kohno T; Yatabe Y; Suto A; Yamamoto Y
Cancer Res; 2022 Sep; 82(18):3236-3248. PubMed ID: 35852797
[TBL] [Abstract][Full Text] [Related]
8. Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH.
Aubele M; Mattis A; Zitzelsberger H; Walch A; Kremer M; Welzl G; Höfler H; Werner M
Int J Cancer; 2000 Jan; 85(1):82-6. PubMed ID: 10585588
[TBL] [Abstract][Full Text] [Related]
9. Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma
Pareja F; Brown DN; Lee JY; Da Cruz Paula A; Selenica P; Bi R; Geyer FC; Gazzo A; da Silva EM; Vahdatinia M; Stylianou AA; Ferrando L; Wen HY; Hicks JB; Weigelt B; Reis-Filho JS
Clin Cancer Res; 2020 Jul; 26(14):3682-3693. PubMed ID: 32220886
[TBL] [Abstract][Full Text] [Related]
10. miRNAs as Biomarkers for Predicting the Progression of Ductal Carcinoma in Situ.
Hannafon BN; Ding WQ
Am J Pathol; 2018 Mar; 188(3):542-549. PubMed ID: 29246496
[TBL] [Abstract][Full Text] [Related]
11. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.
Hernandez L; Wilkerson PM; Lambros MB; Campion-Flora A; Rodrigues DN; Gauthier A; Cabral C; Pawar V; Mackay A; A'Hern R; Marchiò C; Palacios J; Natrajan R; Weigelt B; Reis-Filho JS
J Pathol; 2012 May; 227(1):42-52. PubMed ID: 22252965
[TBL] [Abstract][Full Text] [Related]
12. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
[TBL] [Abstract][Full Text] [Related]
14. Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.
Kim SY; Jung SH; Kim MS; Baek IP; Lee SH; Kim TM; Chung YJ; Lee SH
Oncotarget; 2015 Apr; 6(10):7597-607. PubMed ID: 25831047
[TBL] [Abstract][Full Text] [Related]
15. Loss of FAT1 during the progression from DCIS to IDC and predict poor clinical outcome in breast cancer.
Wang L; Lyu S; Wang S; Shen H; Niu F; Liu X; Liu J; Niu Y
Exp Mol Pathol; 2016 Feb; 100(1):177-83. PubMed ID: 26721716
[TBL] [Abstract][Full Text] [Related]
16. Does concomitant ductal carcinoma in situ affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: An Asian perspective.
Lee WP; Shetty SS; Seah CMJ; Tan PT; Tan SM
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1646. PubMed ID: 35892151
[TBL] [Abstract][Full Text] [Related]
17. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity analyses of asynchronous lesions of ductal carcinoma in situ and invasive ductal carcinoma of the human breast.
Amari M; Moriya T; Ishida T; Harada Y; Ohnuki K; Takeda M; Sasano H; Horii A; Ohuchi N
Jpn J Clin Oncol; 2003 Nov; 33(11):556-62. PubMed ID: 14711979
[TBL] [Abstract][Full Text] [Related]
19. Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression.
Heselmeyer-Haddad K; Berroa Garcia LY; Bradley A; Ortiz-Melendez C; Lee WJ; Christensen R; Prindiville SA; Calzone KA; Soballe PW; Hu Y; Chowdhury SA; Schwartz R; Schäffer AA; Ried T
Am J Pathol; 2012 Nov; 181(5):1807-22. PubMed ID: 23062488
[TBL] [Abstract][Full Text] [Related]
20. Learning to distinguish progressive and non-progressive ductal carcinoma in situ.
Casasent AK; Almekinders MM; Mulder C; Bhattacharjee P; Collyar D; Thompson AM; Jonkers J; Lips EH; van Rheenen J; Hwang ES; Nik-Zainal S; Navin NE; Wesseling J;
Nat Rev Cancer; 2022 Dec; 22(12):663-678. PubMed ID: 36261705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
